



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/046,420	10/26/2001	Richard Voellmy		5843
7590	04/22/2005		EXAMINER	
Richard Voellmy Dept. of Biochem. & Mol. Biol. University of Miami School of Medicine 1011 N.W. 15th St. Miami, FL 33136			WINKLER, ULRIKE	
			ART UNIT	PAPER NUMBER
			1648	
			DATE MAILED: 04/22/2005	

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)
	10/046,420	VOELLMY, RICHARD
	Examiner Ulrike Winkler	Art Unit 1648

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on 03 November 2004.
 2a) This action is FINAL. 2b) This action is non-final.
 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) Claim(s) 24 and 28-36 is/are pending in the application.
 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
 5) Claim(s) _____ is/are allowed.
 6) Claim(s) 24,28-30 and 35 is/are rejected.
 7) Claim(s) 31-34, 36 is/are objected to.
 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.
 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) Notice of References Cited (PTO-892)
 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)
 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
 Paper No(s)/Mail Date _____

4) Interview Summary (PTO-413)
 Paper No(s)/Mail Date. _____

5) Notice of Informal Patent Application (PTO-152)

6) Other: _____

DETAILED ACTION

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on November 3, 2004 has been entered.

Claim Rejections - 35 USC § 112

The rejection of claims 24 and newly added claims 28-30 and 35 under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention **is maintained** for reason of record. Applicants' arguments have been fully considered but fail to persuade. Applicants' argument is that similar claims have been allowed in a prior application and therefore the instant claims are allowable is not convincing. Applicant is reminded that each application is examined for its own merits. Applicants have not addressed the substance of the rejection by arguing that similar claims have previously been allowed. Applicants have only described their invention based on function, yet the correlation between structure and function is not known. The claims encompass a genus of nucleic acids defined only by their function wherein the relationship between the structural features of members of the genus and said function have not been defined. In the absence of such a relationship either disclosed in the as

filed application or which would have been recognized based upon information readily available to one skilled in the art, the skilled artisan would not know how to make and use compounds that lack structural definition. The fact that one could have assayed a nucleic acids of interest does not overcome this defect since one would have no knowledge beforehand as to whether or not any given compound (other than those that might be particularly disclosed in an application) would fall within the scope of what is claimed. It would require undue experimentation (be an undue burden) to randomly screen undefined nucleic acids for the claimed activity. The rejection is maintained.

The rejection of claims 24 and newly added claims 28-30 and 35 under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention **is maintained** for reasons of record. Applicants' arguments have been fully considered but fail to persuade. Applicants' argument is that similar claims have been allowed in a prior application and therefore the instant claims are allowable is not convincing. Applicant is reminded that each application is examined for its own merits. Applicants have not addressed the substance of the rejection by arguing that similar claims have previously been allowed. Applicants have only described their invention based on function, yet the correlation between structure and function is not known. The specification does not provide any guidance on how to predictably manipulate (how to make and use) or mutate undiscovered and undisclosed transcription factors so that they will stay in the active form once stimulated. Thus the artisan would not have been unable to have prepared the

claimed nucleic acid [molecular circuit] without undue experimentation. This claim fails to meet the enablement requirement for the “how to make” prong of 35 U.S.C. § 112 first paragraph.

New rejections:

Claim Objections

Claims 31-34 and 36 are objected to under 37 CFR 1.75(c) as being in improper form because a multiple dependent claim cannot depend from any other multiple dependent claim. See MPEP § 608.01(n). Accordingly, the claims 31-34 and 36 have not been further treated on the merits.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 24 and 28 are rejected under 35 U.S.C. 102(b) as being anticipated by Wu et al. (Journal of Bacteriology 1997).

A narrow reading of the instant claims is that the claims are drawn a heat shock factor (a transcription factor) that that is activated by stress (such as high temperature) that then allows the transcription factor to bind to the promoter which in turn activated the transcription of the gene encoding the transcription factor. The limitation of the “gene of interest” does not indicate that this gene needs to be a heterologous gene or

cannot be the gene for the transcription factor itself. The limitation that the nucleic acid or molecular circuit be “delivered into a cell” is not given patentable weight because the instant claims are drawn to a product. The “delivered into a cell” limitation is read to be a product by process limitation. For this office action, the preamble of the product by process were interpreted as “a composition of matter.” Product by process claims are not limited to the manipulations of the recited steps, only to the structure implied by the steps. M.P.E.P. Section 2113 states that:

“[E]ven though product-by-process claims are limited by and defined by the process, determination of patentability is based on the product itself. The patentability of a product does not depend on its method of production. If the product in the product-by-process claim is the same as or obvious from a product of the prior art, the claim is unpatentable even though the prior product was made by a different process.” *In re Thorpe*, 777 F.2d 695, 698, 227 USPQ 964, 966 (Fed. Cir. 1985) (citations omitted)

Wu et al disclose a *Caulobacter* heat shock sigma factor which is activated by stress and associates with the promoter that is responsible for transcribing more of the heat shock factor (see figure 7). The heat shock factor itself can then bind to the promoter to produce more heat shock factor. Therefore, the instant invention is anticipated by Wu et al.

Conclusion

No claims allowed.

Papers related this application may be submitted to Group 1600 by facsimile transmission. Papers should be faxed to Group 1600 via the PTO Fax Center. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG (November 15, 1989). The Group 1600 Official Fax number is: (703) 872-9306.


Art Unit: 1648

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Tech Center representative whose telephone number is (571)-272-1600.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ulrike Winkler, Ph.D. whose telephone number is 571-272-0912. The examiner can normally be reached M-F, 8:30 am - 5 pm. The examiner can also be reached via email [ulrike.winkler@uspto.gov].

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James Housel, can be reached at 571-272-0902.


ULRIKE WINKLER, PH.D.
PRIMARY EXAMINER
4/15/05